Literature DB >> 18250618

A case of thyrotropin-producing pituitary adenoma, accompanied by an increase in anti-thyrotropin receptor antibody after tumor resection.

K Kageyama1, H Ikeda, S Sakihara, T Nigawara, K Terui, S Tsutaya, E Matsuda, M Shoji, M Yasujima, T Suda.   

Abstract

We describe a rare, but interesting, case of TSH-producing adenoma (TSHoma), accompanied by increases in both anti-TSH receptor antibody (TRAb) and thyroid-stimulating antibody (TSAb) after tumor resection. A 21-yr-old woman was referred to our department for further evaluation of pituitary tumor. In a nearby hospital, she had been diagnosed as having pituitary tumor. Her serum free T4, free T3, and TSH levels were all elevated concomitantly. On the basis of a diagnosis of pituitary adenoma with TSH production, transsphenoidal resection of the pituitary adenoma was performed. Two weeks after the operation, the blood concentrations of TSH were undetectable, whereas both TRAb and TSAb levels were elevated. TSAb levels gradually increased further from 2 weeks to 3 months after the operation, accompanied by an increase in TSH and free T4 levels. TSH is an important hormone in maintaining physiology and regulating immunomodulators in thyrocytes, as it can influence a variety of immune-regulating cytokine-like activities and inhibit expressions of Fas antigen, intracellular adhesion molecule-1, and class II trans-activator. Changes in TSH would modulate the immune circumstances in the thyroid, and then induce TRAb and TSAb. Autoimmune parameters with thyroid function should be observed carefully when managing patients with TSHoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18250618     DOI: 10.1007/BF03349244

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene.

Authors:  J Pohlenz; R E Weiss; P E Macchia; S Pannain; I T Lau; H Ho; S Refetoff
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

2.  Thyrotropin modulates interferon-gamma-mediated intercellular adhesion molecule-1 gene expression by inhibiting Janus kinase-1 and signal transducer and activator of transcription-1 activation in thyroid cells.

Authors:  J Chung; E S Park; D Kim; J M Suh; H K Chung; J Kim; H Kim; S J Park; O Y Kwon; H K Ro; M Shong
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

Review 3.  Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid.

Authors:  John R Klein
Journal:  Autoimmunity       Date:  2003 Sep-Nov       Impact factor: 2.815

4.  The positive regulation of human thyrotropin (TSH) receptor messenger ribonucleic acid by recombinant human TSH is at the intranuclear level.

Authors:  G K Huber; S P Weinstein; P N Graves; T F Davies
Journal:  Endocrinology       Date:  1992-05       Impact factor: 4.736

5.  Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.

Authors:  K Kasagi; H Hatabu; Y Tokuda; Y Iida; K Endo; J Konishi
Journal:  Clin Endocrinol (Oxf)       Date:  1988-10       Impact factor: 3.478

6.  Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro.

Authors:  A Kawakami; K Eguchi; N Matsuoka; M Tsuboi; Y Kawabe; N Ishikawa; K Ito; S Nagataki
Journal:  Endocrinology       Date:  1996-08       Impact factor: 4.736

7.  Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.

Authors:  T Kubo; J Toki; Y Kado; M Kurihara; T Moriwake; S Kanzaki; Y Seino
Journal:  Endocr J       Date:  2000-04       Impact factor: 2.349

8.  Positive regulation of human thyrotropin receptor mRNA by thyrotropin.

Authors:  G K Huber; E S Concepcion; P N Graves; T F Davies
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

Review 9.  Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment.

Authors:  N Sanno; A Teramoto; R Y Osamura
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

10.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more
  3 in total

1.  Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism.

Authors:  Mahdi Kamoun; Michèle d'Herbomez; Christine Lemaire; Armelle Fayard; Rachel Desailloud; Damien Huglo; Jean-Louis Wemeau
Journal:  Eur Thyroid J       Date:  2013-11-20

2.  A remarkable case of thyrotoxicosis initially caused by graves' disease followed by a probable TSHoma - a case report.

Authors:  Mark Quinn; Waiel Bashari; Diarmuid Smith; Mark Gurnell; Amar Agha
Journal:  BMC Endocr Disord       Date:  2020-08-27       Impact factor: 2.763

Review 3.  Concurrent Graves' Disease and TSH Secreting Pituitary Adenoma Presenting Suppressed Thyrotropin Levels: A Case Report and Review of the Literature.

Authors:  Jinrong Fu; Anhua Wu; Xiaoli Wang; Haixia Guan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.